Peri-operative management of antiplatelet therapy in patients with coronary artery disease

Summary

An increasing number of patients suffering from cardiovascular disease, especially coronary artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major adverse events. Unfortunately, there are no specific, widely accepted recommendations for the perioperative management of patients receiving antiplatelet therapy. Therefore, members of the Perioperative Haemostasis Group of the Society on Thrombosis and Haemostasis Research (GTH), the Perioperative Coagulation Group of the Austrian Society for Anesthesiology, Reanimation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society of Cardiology (ESC) have created this consensus position paper to provide clear recommendations on the perioperative use of antiplatelet agents (specifically with semi-urgent and urgent surgery), strongly supporting a multidisciplinary approach to optimize the treatment of individual patients with coronary artery disease who need major cardiac and non-cardiac surgery. With planned surgery, drug eluting stents (DES) should not be used unless surgery can be delayed for ≥12 months after DES implantation. If surgery cannot be delayed, surgical revascularisation, bare-metal stents or pure balloon angioplasty should be considered. During ongoing antiplatelet therapy, elective surgery should be delayed for the recommended duration of treatment. In patients with semi-urgent surgery, the decision to prematurely stop one or both antiplatelet agents (at least 5 days pre-operatively) has to be taken after multidisciplinary consultation, evaluating the individual thrombotic and bleeding risk. Urgently needed surgery has to take place under full antiplatelet therapy despite the increased bleeding risk. A multidisciplinary approach for optimal antithrombotic and haemostatic patient management is thus mandatory.

Keywords

Antiplatelet agents - surgery - atherothrombosis - coronary syndrome - atherosclerosis

• References

• 1 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 2 Mahoney EM, Wang K, Arnold SV. et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010; 121: 71-79.
• 3 Devereaux PJ, Goldman L, Yusuf S. et al. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ 2005; 173: 779-788.
• 4 Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71-82.
• 5 Kallis P, Tooze JA, Talbot S. et al. Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. Eur J Cardiothorac Surg 1994; 8: 404-409.
• 6 Ray JG, Deniz S, Olivieri A. et al. Increased blood product use among coronary artery bypass patients prescribed pre-operative aspirin and clopidogrel. BMC Cardiovasc Disord 2003; 3: 3.
• 7 Alghamdi AA, Moussa F, Fremes SE. Does the use of pre-operative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis. J Card Surg 2007; 22: 247-256.
• 8 Sun JC, Whitlock R, Cheng J. et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
• 9 Anekstein Y, Tamir E, Halperin N. et al. Aspirin therapy and bleeding during proximal femoral fracture surgery. Clin Orthop Relat Res 2004; 418: 205-208.
• 10 Oscarsson A, Gupta A, Fredrikson M. et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305-312.
• 11 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-1302.
• 12 Narendran N, Williamson TH. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand 2003; 81: 38-40.
• 13 Burger W, Chemnitius JM, Kneissl GD. et al. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257: 399-414.
• 14 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs 2004; 4: 151-158.
• 15 Fisher M, Knappertz V. The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Curr Med Res Opin 2006; 22: 1239-1248.
• 16 McIlroy DR, Myles PS, Phillips LE. et al. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. Br J Anaesth 2009; 102: 168-178.
• 17 Shakur H, Roberts I, Bautista R. et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
• 18 Wilson SH, Fasseas P, Orford JL. et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234-240.
• 19 Schouten O, van Domburg RT, Bax JJ. et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49: 122-124.
• 20 Rabbitts JA, Nuttall GA, Brown MJ. et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 2008; 109: 596-604.
• 21 Berger JS, Frye CB, Harshaw Q. et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693-1701.
• 22 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 23 Ebrahimi R, Dyke C, Mehran R. et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009; 53: 1965-1972.
• 24 Song SW, Youn YN, Yi G. et al. Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome. Circ J 2008; 72: 626-632.
• 25 McDonald SB, Renna M, Spitznagel EL. et al. Pre-operative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients. J Cardiothorac Vasc Anesth 2005; 19: 4-10.
• 26 Jones HU, Muhlestein JB, Jones KW. et al. Early post-operative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding. Ann Thorac Surg 2005; 80: 518-522.
• 27 Chapman TW, Bowley DM, Lambert AW. et al. Haemorrhage associated with combined clopidogrel and aspirin therapy. Eur J Vasc Endovasc Surg 2001; 22: 478-479.
• 28 Moore M, Power M. Perioperative hemorrhage and combined clopidogrel and aspirin therapy. Anesthesiology 2004; 101: 792-794.
• 29 Ernst A, Eberhardt R, Wahidi M. et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129: 734-737.
• 30 Linos A, Worthington JW, O’Fallon W. et al. Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. Mayo Clin Proc 1978; 53: 581-586.
• 31 Manson JE, Grobbee DE, Stampfer MJ. et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990; 89: 772-776.
• 32 Final report on the aspirin component of the ongoing Physicians’ Health Study.. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321: 129-135.
• 33 Manson JE, Stampfer MJ, Colditz GA. et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. J Am Med Assoc 1991; 266: 521-527.
• 34 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.. The Medical Research Council‘s General Practice Research Framework. Lancet 1998; 351: 233-241.
• 35 Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-410.
• 36 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. J Am Med Assoc 2010; 303: 841-848.
• 37 Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. Br Med J 2000; 321: 13-17.
• 38 De Berardis G, Sacco M, Strippoli GF. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Br Med J 2009; 339: b4531.
• 39 Leung WY, So WY, Stewart D. et al. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study. Cardiovasc Diabetol 2009; 8: 57.
• 40 Doutremepuich C, Aguejouf O, Desplat V. et al. Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation. Thromb Haemost 2010; 103: 171-180.
• 41 Morimoto T, Fukui T, Lee TH. et al. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 2004; 117: 459-468.
• 42 Silagy CA, McNeil JJ, Donnan GA. et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-89.
• 43 Nelson MR, Liew D, Bertram M. et al. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. Br Med J 2005; 330: 1306.
• 44 Nelson M, Reid C, Beilin L. et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003; 20: 897-903.
• 45 Aspirin for the prevention of cardiovascular disease: U.S.. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.
• 46 Connor AM, Laposata M. A rapid assay for platelet thromboxane production and its use in assessing prior aspirin ingestion. Am J Clin Pathol 1988; 89: 216-221.
• 47 Cahill RA, McGreal GT, Crowe BH. et al. Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg 2005; 200: 564-573 quiz A59–61.
• 48 Breddin K, Loew D, Lechner K. et al. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980; 62: V63-72.
• 49 Juul-Moller S, Edvardsson N, Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-1425.
• 50 Ridker PM, Manson JE, Gaziano JM. et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-839.
• 51 Biondi-Zoccai GG, Lotrionte M, Agostoni P. et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-2674.
• 52 Frilling B, Schiele R, Gitt AK. et al. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study. Am Heart J 2004; 148: 306-3011.
• 53 Algra A, van Gijn J. Is clopidogrel superior to aspirin in secondary prevention of vascular disease?. Curr Control Trials Cardiovasc Med 2000; 1: 143-145.
• 54 Luckie M, Khattar RS, Fraser D. Non-cardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 2009; 95: 1303-1308.
• 55 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
• 56 Silber S, Albertsson P, Aviles FF. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
• 57 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
• 58 Grines CL, Bonow RO, Casey Jr. DE. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-818.
• 59 Byrne RA, Schulz S, Mehilli J. et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009; 157: 620-624e2.
• 60 Park SJ, Park DW, Kim YH. et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
• 61 Lip GY, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
• 62 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
• 63 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
• 64 Vicenzi MN, Meislitzer T, Heitzinger B. et al. Coronary artery stenting and non-cardiac surgery--a prospective outcome study. Br J Anaesth 2006; 96: 686-693.
• 65 Campo G, Fileti L, Valgimigli M. et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 2010; 30: 319-331.
• 66 Sofi F, Marcucci R, Gori AM. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
• 67 Sibbing D, Morath T, Braun S. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
• 68 Zurn CS, Geisler T, Gawaz M. ADP-receptor blockade: A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
• 69 Bal Dit Sollier C, Berge N, Boval B. et al. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010; 104: 571-581.
• 70 Siller-Matula JM, Gouya G, Wolzt M. et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102: 397-403.
• 71 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
• 72 Grines CL, Bonow RO, Casey Jr. DE. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-739.
• 73 Albaladejo P, Marret E, Piriou V. et al. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth 2006; 97: 580-582.
• 74 Wilczynski M, Bochenek T, Goral J. et al. [Bridging by eptifibatide on patients with acute stent thrombosis, requiring urgent surgical revascularisation – report of 2 cases.]. Kardiol Pol 2009; 67: 1313-1316.
• 75 Savonitto S, D’Urbano M, Caracciolo M. et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104: 285-291.
• 76 Montalescot G, Sideris G, Cohen R. et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223.
• 77 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 78 Zafar MU, Ibanez B, Choi BG. et al. A new oral antiplatelet agent with potent anti-thrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost 2010; 103: 205-212.
• 79 Mukerji G, Munasinghe I, Raza A. A survey of the perioperative management of urological patients on clopidogrel. Ann R Coll Surg Engl 2009; 91: 313-320.